Literature DB >> 17437889

Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.

Christina Stefanaki1, Kalliopi Stefanaki, Christina Antoniou, Theodoros Argyrakos, Amalia Patereli, Alexander Stratigos, Andreas Katsambas.   

Abstract

BACKGROUND: Deregulated cell cycle control is one of the hallmarks of tumor development. The expression of different cell cycle regulators has been used in various neoplasms as an adjunct to diagnosis.
OBJECTIVE: We sough to determine the expression of cell cycle and apoptosis regulators in Spitz nevi and to appraise its value as a diagnostic adjunct in the differential diagnosis from melanomas and common nevi.
METHODS: Ki-67, p-27, p-16, p-53, p-21, Rb, cyclin D1, cyclin A, cyclin B1, bcl-2, and bax expression was assessed by immunohistochemistry in 10 Spitz nevi and was compared with 16 melanomas and 20 common nevi immunohistochemical expression.
RESULTS: P-27 (60% +/- 20.13), p-16 (62.00% +/- 10.85), and bcl-2 (46.00% +/- 42.47) were highly expressed in Spitz nevi, whereas Ki-67 (2.80% +/- 2.55), Rb (3.75% +/- 4.55), p-53 (2.30% +/- 0.10), cyclin A (0.70% +/- 1.56), B1 (0.20% +/- 0.34), and bax (2.65% +/- 6.37) demonstrated a limited expression. Cyclin D1 (8.60% +/- 7.30) and p-21 (6.40% +/- 5.37) showed a moderate expression. The expression of bax (P = .001), Ki-67 (P < .0001), Rb (P < .0001), p-16 (P < .0001), cyclin A (P < .0001), and cyclin B1 (P < .0001) was significantly higher in melanomas in comparison with Spitz nevi, whereas p-27 expression was significantly higher in Spitz nevi (P < .0001). A trend for significant difference in favor of melanomas was also observed for p-53 (P = .002). On the other hand, no difference was detected for bcl-2 (P = .275), p-21 (P = .055), or cyclin D1 (P = .077). Spitz nevi demonstrated a trend for a higher expression for p-21 (P = .008) and cyclin D1 (P = .006), whereas they exhibited lower p-16 (P = .004) in comparison with common nevi. LIMITATIONS: The number of Spitz nevi was relatively small.
CONCLUSION: Spitz nevi differ from melanomas in their immunohistochemical pattern of expression of cell cycle and apoptosis regulators and more closely resemble common benign nevi.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437889     DOI: 10.1016/j.jaad.2006.09.015

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

2.  Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma.

Authors:  Bruno Augusto Benevenuto de Andrade; Jorge Esquiche León; Román Carlos; Wilson Delgado-Azañero; Adalberto Mosqueda-Taylor; Oslei Paes de Almeida
Journal:  Head Neck Pathol       Date:  2012-02-05

Review 3.  A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment.

Authors:  Jeong Hee Cho-Vega
Journal:  Mod Pathol       Date:  2016-04-22       Impact factor: 7.842

Review 4.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice.

Authors:  Laura A Vella; Min Yu; Amy B Phillips; Olivera J Finn
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

6.  Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.

Authors:  Sophia A Ma; Conor P O'Day; Tzvete Dentchev; Junko Takeshita; Todd W Ridky; John T Seykora; Emily Y Chu
Journal:  J Cutan Pathol       Date:  2019-02-14       Impact factor: 1.587

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.